NEURONETICS, INC.

Analyst Reco. Neuronetics, Inc.

Equities

STIM

US64131A1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
1.92 ^USD	+1.05%		-11.93%	-33.79%

May. 15	Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents	CI
May. 14	William Blair Upgrades Neuronetics to Outperform From Market Perform	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

William Blair Upgrades Neuronetics to Outperform From Market Perform	May. 14	MT
Canaccord Genuity Adjusts Price Target on Neuronetics to $7 From $9, Maintains Buy Rating	23-03-08	MT
Piper Sandler Adjusts Neuronetics' Price Target to $9 From $10, Reiterates Overweight Rating	22-01-03	MT
NEURONETICS : JMP Securities Adjusts Price Target on Neuronetics to $12 From $18, Maintains Market Outperform Rating	21-10-14	MT
NEURONETICS : William Blair Downgrades Neuronetics to Market Perform From Outperform	21-10-13	MT
NEURONETICS : BTIG Downgrades Neuronetics to Neutral from Buy	21-10-13	MT
NEURONETICS : William Blair Upgrades Neuronetics to Outperform From Market Perform	21-01-22	MT
NEURONETICS : Piper Sandler Adjusts Neuronetics' Price Target to $27 from $20, Keeps Overweight Rating	21-01-21	MT
NEURONETICS : BTIG Research Adjusts Neuronetics PT to $21 From $14, Maintains Buy Rating	21-01-21	MT
NEURONETICS : BTIG Research Adjusts Neuronetics PT to $14 From $10, Maintains Buy Rating	20-12-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer